Vanadyl sulfate inhibits NO production via threonine phosphorylation of eNOS. by Li, Zhuowei et al.
Vanadium was first discovered in 1971 as a
trace element that is essential for normal
growth. Since then, vanadium has been found
to regulate the activity of various enzymes that
induce pronounced changes in metabolic
functions. Some of these enzymes include
Na+,K+ ATPase, acid phosphatase, alkaline
phosphatase, and protein tyrosine phos-
phatases. Its vanadyl (IV) derivative, vanadyl
sulfate (VOSO4), has a potent effect on trans-
portation and metabolism of glucose. 
Humans may be exposed to excessive
vanadium in several situations, for example,
over-consumption of vanadium-rich foods
(e.g., some wines and seafood) (Bu-Olayan
and al-Yakoob 1998; Teissedre et al. 1998),
ingestion of certain dietary regimens, and
inhalation of vanadium-rich environmental
pollutants in certain occupations (Levy et al.
1984; Woodin et al. 1999, 2000). These
occupations include boilermakers and power
plant workers, who are often exposed to high
levels of vanadium-rich compounds at work.
Vanadium exposures have been associated
with acute upper and lower respiratory symp-
toms in these workers (Levy et al. 1984;
Woodin et al. 1999, 2000). 
Exposure to excessive vanadium may also
produce adverse effects on the cardiovascular
system. Rats fed vanadium-containing drinking
water for 2 months developed pulmonary
hypertension (Susic and Kentera 1986).
VOSO4 and vanadium-rich pollutant dust
(residual oil ﬂy ash) produced an acute increase
in pulmonary artery pressure in buffer-perfused
rabbit lungs (Huang et al. 2002) and vasocon-
striction in isolated rat aortic rings (Cadene
et al. 1997). In boilermakers, the vanadium
concentration in particulate air was associated
with increases in the heart rate variability index,
indicating alterations in cardiac autonomic
functions (Magari et al. 2002). The mecha-
nisms by which VOSO4 induced cardiovascu-
lar adverse effects, however, are unclear.
We have shown previously that VOSO4
induced acute pulmonary vasoconstriction in
perfused rabbit lungs and that this effect was
associated with inhibition of nitric oxide pro-
duction (Huang et al. 2002). The inhibition
occurred within 10 min after the administra-
tion of VOSO4, indicating the mechanisms
for the inhibition may be at the levels of
nitric oxide synthase (NOS) activity. Because
phosphorylation of endothelial NOS (eNOS)
is an important posttranslational regulatory
mechanism for its activity, in this study we
investigated the effects of VOSO4 on the
phosphoryation of threonine (Thr) residues
of eNOS, which would inhibit its enzymatic
activity. The hypothesis was tested in isolated
perfused lungs, isolated pulmonary artery
rings, and pulmonary artery endothelial cells.
Materials and Methods
Reagents and chemicals. Vanadyl sulfate
(VOSO4), zinc sulfate, copper, zinc superoxide
dismutase (Cu,ZnSOD), PAPANONOate,
calphostin C, and A23187 (a calcium
ionophore) were obtained from Sigma
Chemical Co. (St. Louis, MO). Human pul-
monary artery endothelial cells and endothe-
lial cell growth medium were purchased from
Cell Applications, Inc. (San Diego, CA), and
the monoclonal antibodies to phospho-
threonine and phosphoserine were purchased
from Alexis Corp. (San Diego, CA). Rabbit
anti-phosphothreonin(495) (phospho-Thr495)
eNOS, mouse anti-phosphotyrosine (PY99),
rabbit anti-eNOS (NOS3, N-20), rabbit
anti-p-Akt1(serine at codon 473), goat anti-
human Akt, protein A agarose, and secondary
antibodies (both horseradish peroxidase-con-
jugated and fluorescein-conjugated) were
obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Molecular mass standards,
polyacrylamide, and buffers were purchased
from Bio-Rad (Richmond, CA). We obtained
ECL Western blotting detection reagents
from Amersham Pharmacia Biotechnology
(Piscataway, NJ).
Isolated perfused rabbit lung. The isolated
buffer-perfused lung (IPL) model using male
New Zealand white rabbits (Robinson’s Farm,
Clemens, NC) weighing 2.5–3.0 kg has been
described previously (Huang et al. 2002).
Briefly, the pulmonary artery and the left
atrium were cannulated for monitoring the
mean pulmonary artery pressure and the left
atrial pressure, respectively. A reservoir was
connected with the perfusion circuit down-
stream from the left atrium and was sus-
pended freely from a force displacement
transducer (Model FT100; Grass Instrument
Environmental Health Perspectives • VOLUME 112 | NUMBER 2 | February 2004 201
Address correspondence to: Y-C. T. Huang, CB 7315,
104 Mason Farm Road, Chapel Hill, NC 27599,
USA. Telephone: (919) 843-9504. Fax: (919) 966-
6271. E-mail: huang.tony@epa.gov
We thank C. Marshall of Duke University Medical
Center for procuring rat pulmonary artery rings and
J. Soukup of the U.S. EPA for measuring nitrite/
nitrate in the samples.
The research described in this article has been
reviewed by the Health Effects and Environmental
Research Laboratory, U.S. EPA, and has been
approved for publication. Approval does not signify
that the contents necessarily reﬂect the views and poli-
cies of the agency, nor does mention of the trade
names or commercial products constitute endorsement
or recommendation for use.
The authors declare they have no competing ﬁnancial
interests.
Received 23 May 2003; accepted 22 October 2003.
Research | Article
Vanadyl Sulfate Inhibits NO Production via Threonine Phosphorylation 
of eNOS
Zhuowei Li,1 Jacqueline D. Carter,2 Lisa A. Dailey,2 and Yuh-Chin T. Huang2
1Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina, Chapel Hill, North Carolina, USA; 2National
Health and Environmental Effects Research Laboratory, Ofﬁce of Research and Development, U.S. Environmental Protection Agency,
Research Triangle Park, North Carolina, USA
Exposure to excessive vanadium occurs in some occupations and with consumption of some
dietary regimens for weight reduction and body building. Because vanadium is vasoactive, individ-
uals exposed to excessive vanadium may develop adverse vascular effects. We have previously
shown that vanadyl sulfate causes acute pulmonary vasoconstriction, which could be attributed in
part to inhibition of nitric oxide production. In the present study we investigated whether NO
inhibition was related to phosphorylation of endothelial nitric oxide synthase (eNOS). VOSO4
produced dose-dependent constriction of pulmonary arteries in isolated perfused lungs and pul-
monary arterial rings and a right shift of the acetylcholine-dependent vasorelaxation curve.
VOSO4 inhibited constitutive as well as A23187-stimulated NO production. Constitutive NO
inhibition was accompanied by increased Thr495 (threonine at codon 495) phosphorylation of
eNOS, which would inhibit eNOS activity. Thr495 phosphorylation of eNOS and inhibition of
NO were partially reversed by pretreatment with calphostin C, a protein kinase C (PKC)
inhibitor. There were no changes in Ser1177 (serine at codon 1177) or tyrosine phosphorylation of
eNOS. These results indicate that VOSO4 induced acute pulmonary vasoconstriction that was
mediated in part by the inhibition of endothelial NO production via PKC-dependent phosphory-
lation of Thr495 of eNOS. Exposure to excessive vanadium may contribute to pulmonary vascular
diseases. Key words: boilermakers, protein kinase C, pulmonary hypertension, vanadium. Environ
Health Perspect 112:201–206 (2004). doi:10.1289/ehp.6477 available via http://dx.doi.org/
[Online 22 October 2003]Company, Quincy, MA) for monitoring the
weight gain of the lung. The reservoir was
placed at the lowest portion of the lung to
maintain a left atrial pressure of zero. The per-
fusion circuit also consisted of a roller pump, a
bubble trap, and a heat exchanger connected
with Tygon tubing. The volume of the system
was approximately 250 mL. The trachea was
also cannulated for monitoring tracheal pres-
sure. The lung was ventilated with 21% O2 +
5% CO2 through the tracheostomy using an
animal respirator delivering 30 breaths/min at
2–3 cm H2O positive end-expiratory pressure.
The tidal volume was adjusted to achieve a
peak tracheal pressure of 7–10 mmHg
(~20 mL). All pressures and weight gain were
transmitted to a 4-channel analog-to-digital
converter and amplifier connected to a per-
sonal computer equipped with data acquisition
software (DATAQ; DATAQ Instruments, Inc.
Akron, OH). After the pulmonary circulation
was washed free of blood with Krebs-Henseleit
(KH)-3% albumin buffer (82.8 mM sodium
chloride, 4.7 mM potassium chloride,
2.4 mM monobasic potassium phosphate,
25 mM sodium bicarbonate, 1.2 mM magne-
sium sulfate, 2.7 mM calcium chloride,
11.1 mM dextrose, and 3% w/v bovine serum
albumin, fraction V at a pH of 7.3–7.4), a
recirculated perfused lung system with a ﬂow
of 100 mL/min was established. The lung was
then allowed to stabilize for 10–15 min.
Lungs with visible leaks and/or high pul-
monary artery pressure (> 20 mmHg) during
this period were excluded.
Measurements of microvascular pressure
and pulmonary vascular resistance. At the
end of the experiments, we measured the
microvascular pressure (Pmv) using the double
occlusion technique (Linehan et al. 1982).
Pulmonary vascular resistance was partitioned
into upstream (arterial; Ra) and downstream
(venous; Rv) resistance using the following
equations: 
where Pla is left atrial pressure. In our study,
the ﬂow was a constant at 100 mL/min, and
Pla was set at zero.
Isolated rat pulmonary artery ring.
Segments of the right and left main pul-
monary arteries of Sprague-Dawley rats
(250–350 g) approximately 2–3 mm in
length were removed carefully and placed in
KH buffer. The artery segments were then
suspended in the Radnoti 4-unit organ bath
system (Glass Technology Inc., Monrovia,
CA). Each reservoir held 20 mL of KH buffer
and was bubbled constantly with a 21% O2 +
5% CO2 gas mixture. After a 10–15 min sta-
bilization period, the baseline tension of the
rings was adjusted to 1 g before all experi-
ments. In acetylcholine experiments, all rings
were preconstricted with 1 µM phenylephrine.
The degree of relaxation and constriction was
expressed as a percentage of constriction
induced by 1 µM phenylephrine. 
Cultured human pulmonary artery
endothelial cells (HPAEC). HPAEC (Cell
Applications, Inc. San Diego, CA) were cul-
tured in the endothelial cell growth medium
in 6-well plates and were used during passages
3–5. HPAEC were isolated from normal
human pulmonary arteries and have been
shown to respond to a variety of vasoactive
substances (Ryan et al. 1976a; 1976b).
Measurements of nitrite/nitrate. To deter-
mine the production of NO, we measured
nitrite/nitrate concentrations in serial perfusate
samples and in the culture medium of HPAEC
by the Griess reaction using a colorimetric
nitrite/nitrate assay kit (Nitric Oxic Assay Kit;
R &D Systems, Minneapolis, MN).
Immunoprecipitation and Western blot.
Confluent HPAEC cells were washed once
with ice-cold phosphate-buffered saline
(PBS) and then lysed with RIPA buffer
(1% Nonidet P-40, 0.5% sodium deoxy-
cholate, 0.1% SDS in PBS, pH 7.4) contain-
ing 0.1 mM VOSO4 and protease inhibitors
(0.5 mg/mL aprotinin, 0.5 mg/mL E-64,
0.5 mg/mL pepstatin, 0.5 mg/mL bestatin,
10 mg/mL chymostatin, 0.1 ng/mL leu-
peptin). Cells were scraped up and passed
through a 21-gauge needle 3–5 times. The cell
samples were then centrifuged at 3,000 × g for
10 min at 4°C and the supernatants were col-
lected. For immunoprecipitation, the super-
natant samples were pre-cleared with protein
A-agarose for 30 min at 4°C and centrifuged
at 10,000 × g for 1 min. A rabbit anti-human
eNOS antibody (1 µg) was added to the
supernatant (250 µg) and incubated for 2 hr at
4°C, followed by another 2-hr incubation
with 20 µL protein A-agarose at 4°C with
end-to-end rotation. After centrifugation at
10,000 × g for 1 min, the pellets were col-
lected, washed twice with 500 µL ice-cold
RIPA buffer and once with ice-cold PBS,
resuspended in electrophoresis sample buffer,
and boiled for 5 min. Supernatant samples
were then separated by 7.5% SDS-PAGE and
transferred to a polyvinylidene difluoride
(PVDF) membrane. The blots were blocked
with 3% gelatin in TBS for 2 hr at room
temperature and probed with antibodies
against phosphothreonine, phosphoserine, or
phosphotyrosine (PY99) overnight at 4°C.
This was followed by incubation with appro-
priate HRP-conjugated secondary antibodies.
To determine the amount of eNOS, the blot
was stripped and reprobed with a rabbit
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Figure 1. Effects of VOSO4 on IPL. (A) Changes in mean Ppa in IPL treated with VOSO4, which was injected
into the pulmonary artery and monitored for 40 min. (B) Pulmonary vascular resistance [upstream (Ra) and
downstream (Rv)] in IPL treated with 5 µM VOSO4.
*p < 0.05 versus control; n = 7–9.
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Figure 2. VOSO4-induced constriction in (A) rat pulmonary artery rings (expressed as percentage of vaso-
constriction produced by 1 µM phenylephrine, with ZnSO4 used as a negative control) and (B) isolated per-
fused lung (expressed as the change in mean Ppa).
*p < 0.05 versus ZnSO4.
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▲ ▲anti-human eNOS antibody and HRP-conju-
gated goat anti-rabbit IgG. Bands were
detected using chemiluminescence reagents
and ﬁlm.
Immunocytochemical staining of phos-
phorylated eNOS. HPAEC grown on slides
were treated with VOSO4 (50 µM) for
10 min. The cells were fixed with 4%
paraformaldehyde and blocked with 3% don-
key serum. The ﬁxed cells were probed with
an antibody against phospho-Thr495 eNOS
overnight at 4°C followed by incubation with
a fluorescein-conjugated secondary antibody
for 30 min. Images were examined under a
ﬂuoresence microscope equipped with a ﬂuo-
rescein isothiocyanate ﬁlter. Photographs were
taken using a digital camera system (Nikon
Microphot-SA; Southern MicroInstruments,
Marietta, GA) and imaging software (ACT-1,
version 2.10, Nikon).
Statistical analysis. We present data as
mean ± SE. Time-series data were analyzed
using repeated measures analysis of variance
(ANOVA). We evaluated differences among
groups at selective time points using one-way
ANOVA followed by the Fisher protected
least-signiﬁcant-difference post-hoc test. The
statistical analysis was performed using
Statview software (SAS Institute Inc., Cary,
NC). We report actual p-values where statisti-
cal analyses were performed. A p-value of
< 0.05 was considered statistically signiﬁcant. 
Results
VOSO4-induced pulmonary artery constriction.
The baseline mean pulmonary artery pressure
of the IPL was 13 ± 1 mmHg. Vanadyl sulfate
at 0.5 µM injected into the pulmonary artery
produced a transient increase in pulmonary
artery pressure, which peaked at 5 min and
returned to the baseline by 40 min (Figure 1A).
At 5 µM, VOSO4 produced an acute and per-
sistent increase in pulmonary artery pressure,
which plateaued at approximately 24 mmHg
after 20 min. At 50 µM, VOSO4 produced
such severe pulmonary hypertension and lung
edema that the IPL could not be sustained for
40 min. All subsequent experiments in IPL
were thus performed with 5 µM of VOSO4. 
The increase in pulmonary vascular resis-
tance induced by VOSO4 was primarily due to
constriction of upstream pulmonary vessels
(Figure 1B). VOSO4 produced vasoconstric-
tion in pulmonary artery rings (Figure 2A) and
IPL, whereas zinc sulfate had little vasoactive
effect (Figure 2B). 
VOSO4 shifted the acetylcholine-induced
vasorelaxation curve to the right (Figure 3A) in
pulmonary artery rings, which is consistent
with a loss of vasodilatory activity of NO.
Inhibition of NO production by an NOS
inhibitor, L-NAME, increased pulmonary
artery pressure in our IPL system (Huang et al.
1997). VOSO4-induced pulmonary hyperten-
sion was attenuated by an NO donor,
PAPANONOate (1 mM) and Cu,ZnSOD
(Figure 3B and 3C). 
VOSO4 inhibited NO production. In con-
trol IPL, NO production measured as
nitrite/nitrate accumulation in the perfusate
increased gradually over time; the total increase
was 3.4 ± 0.8 µM during 40 min of perfusion
(Figure 4A). VOSO4 (5 µM) inhibited
nitrite/nitrate accumulation, which occurred
as early as 10 min after the treatment. At
40 min, VOSO4 inhibited nitrite/nitrate accu-
mulation by approximately 80%. The average
change in nitrite/nitrate concentration after
40 min of perfusion was decreased to 0.7 ±
0.6 µM (p = 0.003 vs. control) (Figure 4A). In
HPAEC, VOSO4 inhibited constitutive and
A23187-stimulated NO production (Figure 4B
and 4C).
Effect of VOSO4 on eNOS phosphorylation.
In HPAEC, VOSO4 induced an approximately
2-fold increase in Thr phosphorylation of
eNOS (Figure 5A and 5B). Immunostaining
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Figure 4. Inhibition of NO production measured as the accumulation of nitrite/nitrate concentration. (A) Inhibition of NO production in the perfusate of IPL after
treatment with 5 mM VOSO4 (n = 7–9). (B) Inhibition of constitutive NO production by 50 µM VOSO4 in HPAEC (n = 6). (C) Inhibition of A23187-stimulated NO pro-
duction by VOSO4 in HPAEC pretreated simultaneously with VOSO4 and 1 µM A23187 (n = 6). The baseline nitrite/nitrate concentration for HPAEC in (B) and (C)
was pooled from all 12 experiments. 
*p < 0.05 versus control in (A) and (B) and p < 0.05 versus time 0 in (C). #p < 0.05 vs. A23187 alone.
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Figure 3. Effects of VOSO4 on artery rings. (A) Inhibition of acetylcholine (Ach)-induced vasorelaxation by VOSO4 (n = 10–15 separate experiments). (B) Attenuation
of VOSO4-induced pulmonary hypertension by 1 mM PAPANONOate, an NO donor (n = 5–9). (C) Attenuation of VOSO4-induced pulmonary hypertension by 100 U/mL
Cu,ZnSOD (n = 5–9). See “Materials and Methods” for details of experiments.
*p < 0.05 versus control in (A) and p < 0.05 versus VOSO4 for (B) and (C).
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468 1 0with a phospho-Thr495 eNOS antibody was
also increased in VOSO4-treated HPAEC
(Figure 5C). Thr495 was located in the 
calcium–calmodulin binding domain of
eNOS, and phosphorylation of this Thr
residue has been shown to inhibit eNOS activ-
ity (Fulton et al. 2001; Govers and Rabelink
2001). These ﬁndings are consistent with the
VOSO4-induced inhibition of NO produc-
tion stimulated by A23187, which enhances
calcium binding to calmodulin. VOSO4 did
not alter phosphorylation on Ser1177 tyrosine
residues of eNOS or Akt1 phosphorylation
(data not shown).
Effects of protein kinase C inhibitor on
VOSO4 effects. The VOSO4-induced pul-
monary artery hypertension in perfused rabbit
lungs was partially reversed by pretreatment
with calphostin C (0.1 µM), a protein kinase
C (PKC) inhibitor (Figure 6A). The attenua-
tion of pulmonary hypertension was associ-
ated with a reversal of VOSO4-induced
inhibition of NO production (Figure 6B). In
HPAEC, 0.1 µM calphostin C also attenu-
ated VOSO4-induced inhibition of NO pro-
duction (Figure 7A). This was associated with
decreased Thr495 phosphorylation of eNOS
(Figure 7B).
Discussion
Vanadium compounds have been known to
cause vasoconstriction in systemic arteries.
Orthovanadate (V+5) constricts renal arteries
(Benabe et al. 1984; Kumar and Corder
1980; Larsen and Thomsen 1980a, 1980b),
splanchnic arteries (Larsen and Thomsen
1980a), and the aorta (Borchard et al. 1981),
and VOSO4 (V+4) constricts mesenteric arter-
ies and the aorta (Cadene et al. 1997). In the
present study, we showed in intact lungs and
isolated pulmonary artery rings that VOSO4
produced pulmonary artery constriction,
which could be attributed in part to the loss
of vasodilator activity provided by endothelial
NO. This was supported by the inhibition of
nitrite/nitrate accumulation in the perfusate
of IPL and HPAEC and by the rightward
shift of the acetylcholine-induced vasorelax-
ation curve induced by VOSO4. 
VOSO4-induced NO inhibition in our
study was associated with increased Thr495
phosphorylation of eNOS. Thr495 phosphoryla-
tion is one of the few negative posttranslational
mechanisms that regulate eNOS activity
(Fulton et al. 2001; Govers and Rabelink
2001). Many agonist stimuli, such as vascular
endothelial growth factor (VEGF) (Michell
et al. 2001), bradykinin (Fleming et al. 2001;
Harris et al. 2001), and ischemic stress
(Chen ZP et al. 1999), inhibit phosphorylation
at the Thr495 residue. Phosphorylation of
Thr495 by antagonists such as VOSO4, as
shown in our study, would thus interfere with
the binding of calcium–calmodulin and
inhibit eNOS activity. Several previous studies
in systemic arteries have shown that the vana-
dium-induced contraction was related to entry
of extracellular calcium (Benabe et al. 1984;
Cadene et al. 1997). Extracellular calcium
may activate protein phosphatases (e.g., PP1,
PP2A) and dephosphorylate Thr495 (Michell
et al. 2001). 
The mechanism for Thr495 phosphoryla-
tion was partially mediated by activation of
PKC because the PKC inhibitor, calphostin C,
attenuated VOSO4-induced Thr phosphoryla-
tion and restored NO production in HPAEC.
These ﬁndings agree with those in bovine and
porcine aortic endothelial cells, in which PKC
activation phosphorylates Thr495 of eNOS
(Fleming et al. 2001; Michell et al. 2001). 
There are other phosphorylative mecha-
nisms that regulate eNOS activity post-
translationally. Phosphorylation of Ser1177
enhances eNOS activity, a mechanism
shared by many NO agonists such as insulin
(Montagnani et al. 2001; Schnyder et al.
2002), insulin-like growth factor-1 (Michell
et al. 1999), VEGF (Brouet et al. 2001;
Dimmeler et al. 2000; Fulton et al. 1999;
Michell et al. 2001), estrogen (Hisamoto
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Figure 7. Effects of PKC on VOSO4-induced NO inhibition in HPAEC. (A) Time-dependent inhibition of NO
production in HPAEC by 50 µM VOSO4, which was partially reversed by pretreatment with 0.1 µM
calphostin C (CP). (B) Time course of Thr495 phosphorylation of eNOS by 50 µM VOSO4 with or without CP;
n = 4 independent experiments.
*p < 0.05 vs. time 0. #p < 0.05 vs. VOSO4 at respective time points.
Figure 6. Effects of PKC on (A) VOSO4-induced pulmonary hypertension (expressed as the change in mean
Ppa) and (B) NO inhibition in perfused rabbit lungs. VOSO4-induced pulmonary hypertension and NO inhibi-
tion were partially reversed by pretreatment of calphostin C (CP; 0.1 µM), 20 min before the addition of
5µ M VOSO4; n = 5–9. 
*p < 0.05 vs. VOSO4.
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Figure 5. Increases in Thr495 phosphorylation of
eNOS in HPAEC by 50 µM VOSO4 (see “Materials
and Methods” for details). (A) Representative
Western blot of four independent experiments.
(B) Densitometry analysis of (A). (C) Immuno-
fluorescent staining of phospho-Thr495 eNOS.
Bar = 100 µm.
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*et al. 2001), and stress (Boo et al. 2002). In
our study, VOSO4 did not affect Ser phos-
phorylation of eNOS or Akt1. eNOS may
also be phosphorylated at tyrosine residues,
although the functional consequence of the
enzyme is less clear. Tyrosine phosphorylation
of eNOS produced by hydrogen peroxide and
orthovanadate decreased enzyme activity
(Garcia-Cardena et al. 1996). In contrast,
VEGF-, estrogen- or stress-induced eNOS
activation could be inhibited by tyrosine kinase
inhibitors (Ayajiki et al. 1996; Chen Z et al.
1999; Corson et al. 1996; Papapetropoulos
et al. 1997). We did not see tyrosine phospho-
rylation of eNOS in HPAEC exposed to
50 µM of VOSO4, but we could not exclude
tyrosine residues of other proteins functionally
linked to NOS activation. 
Our findings that VOSO4 produces pul-
monary vasoconstriction by inhibiting NOS
activity have several clinical implications. First,
certain occupations, such as boilermakers, are
exposed to fuel oil ash that contains a high
concentration of vanadium (up to 30 µg/m3)
for many hours a day during a boiler overhaul
(Hauser et al. 1995, 1998; Woodin et al.
1999, 2000). Inhalation of vanadium in this
situation has been associated with not only air-
way inflammation and constriction (Hauser
et al. 1995, 2001, 2002; Hessel et al. 1998;
Woodin et al. 1998, 2000) but also cardiovas-
cular effects measured as increased heart rate
variability (Magari et al. 2002). Vanadium
contained in vanadium-rich residual oil ﬂy ash
given intratracheally can gain access into the
pulmonary circulation (Huang et al. 2002). 
Second, certain weight-reduction and
muscle-building regimens contain signiﬁcant
amounts of VOSO4. For example, BioLean
Free contains 400 µg VOSO4 per serving
(four tablets), Mass Appeal contains 5 mg
VOSO4 per serving, and Satiete contains
660 µg of VOSO4 per serving (all from
Wellness International Network, Ltd., Plano,
TX). With the recommended doses of several
servings a day on the label, regular users can
consume a significant amount of VOSO4.
The pulmonary vasoconstrictor property of
VOSO4 demonstrated in our study raised the
possibility of increased risk for pulmonary
hypertension in these individuals, especially in
view of the long elimination half-life of vana-
dium (12 days) after ingestion (Ramanadham
et al. 1991). Indeed, rats fed with vanadium
for 2 months developed pulmonary hyperten-
sion and right ventricular hypertrophy (Susic
and Kentera 1986). 
Vanadium is a unique metal that is known
to avidly permeate cell membranes. Once
inside the cells, vanadium chelates to many
intracellular ligands, such as creatine phos-
phate, proteins, glutathione, and ascorbic
acids (Nechay et al. 1986), and presumably is
detoxiﬁed. When vanadium loads exceed the
capacity of the chelators, however, free
vanadyl ions (V+4) and the more potent vana-
date (V+5) may be released at high local con-
centration and may attack important
biomolecules, resulting in cellular dysfunc-
tion (Hirao 2000; Liochev and Fridovich
1987; Nechay 1984). Our results indicate
that eNOS in endothelial cells is a potential
target. Given the long elimination half-life of
vanadium, the endothelial dysfunction with
loss of NO-mediated vasodilator activity
raised the possibility that individuals exposed
to excessive vanadium in the environment
may be at a greater risk for developing pul-
monary hypertension and perhaps other vas-
cular diseases. Our results indicate the need
for further studies on the prevalence of car-
diovascular diseases in at-risk workers and
individuals consuming vanadium-rich dietary
supplements on a regular basis. 
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